Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1687-1692

  Shi, Juan ^a,b   Zheng, Dexian ^b   Liu, Yanxin ^b   Mai, Har Sham ^a   Tam, Paul ^a   Farzaneh, Farzin ^c   Xu, Ruian ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND [114-281]; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CULTURE; CELL LINE; CONTROLLED STUDY; HISTOLOGY; LIVER; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DEPENDOVIRUS; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; LIVER; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; SURVIVAL RATE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16444381759     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2749     Document Type: Article

References (36)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA cancer J Clin 2001;51:15-36.
2. Giaccone G. Clinical impact of novel treatment strategies. Oncogene 2002;21:6970-81.
3. Johnson BE, Grayson J, Makuch RW, et al. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 1990;8:396-401.
4. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
5. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
6. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
7. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001;61:3330-8.
8. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97:1754-9.
9. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-8.
10. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886-94.
11. Lee J, Hampl M, Albert P, Fine HA. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002;4:312-23.
12. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001;4:257-66.
13. Sova P, Ren XW, Ni S, et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004;9:496-509.
14. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004;10:828-34.
15. Liu YX, Zhu X, Ma ZY. Expression, purification of and biological activity of rsTRAIL in E. coli. Chin Sci Bull 1999;44:1306-9.
16. Xu RA, Janson CG, Mastakov M, et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 2001;8:1323-32.
17. Xiao W, Chirmule N, Schnell MA, Tazelaar J, Hughes JV, Wilson JM. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther 2000;1:323-9.
18. Yamaura T, Murakami K, Doki Y, et al. Solitary lung tumors and their spontaneous metastasis in athymic nude mice orthotopically implanted with human non-small cell lung cancer. Neoplasia 2000;2:315-24.
19. Xu RA, Sun X, Tse L-Y, et al. Long term expression of angiostatin suppresses metastatic liver cancer in mice. Hepatology 2003;37:1451-60.
20. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
21. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996;334:1185-7.
22. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125:509-21.
23. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000;105:1573-87.
24. Walters RW, Yi SM, Keshavjee S, et al. Binding of adeno-associated virus type 5 to 2, 3-linked sialic acid is required for gene transfer. J Biol Chem 2001;276:20610-6.
25. Ye X, Rivera VM, Zoltick P, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999;283:88-91.
26. Shi J, Zheng D, Man K, Fan ST, Xu R. TRAIL: a potential agent for cancer therapy. Curr Mol Med 2003;3:727-36.
27. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
28. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-60.
29. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5.
30. Zhang HG, Xie J, Xu L, et al. Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver. J Virol 2002;76:5692-700.
31. Gibson EM, Henson ES, Haney N, Villanueva J, Gibson SB. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res 2002;62:488-96.
32. Harper N, Farrow SN, Kaptein A, MacFarlene M. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-κB activation by inhibition of apical caspases. J Biol Chem 2001;276:34743-52.
33. Addison CL, Arenberg DA, Morris SB, et al. The CXC chemokine, monokine induced by interferon-α, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000;11:247-61.
34. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 2003;171:1526-33.
35. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003;107:2250-6.
36. Saeki T, Mhashilkar A, Swanson X, et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002;21:4558-66.